19741-14-1

Basic information

• Product Name: 4-[N-(2,4-DIAMINO-6-PTERIDINYLMETHYL)-N-METHYLAMINO] BENZOIC ACID
• Synonyms: 2,4-Diamino-N(10)-methylpteroic acid;4-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoic acid;Deoxyaminopteroic acid;N-10-Methyl-4-deoxy-4-aminopteroate;Nsc 131463;DAMPA;4-[N-[(2,4-DiaMinopyriMido[4,5-b]pyrazin-6-yl)Methyl]-N- MethylaMino]benzoic Acid;4-AMino-4-deoxy-10-Methylpteroic Acid
• CAS NO: 19741-14-1
• Molecular Formula: C₁₅H₁₅N₇O₂
• Molecular Weight: 325.33
• Product Categories: Bases & Related Reagents;Drug Analogues;Heterocycles;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals
• Mol File: 19741-14-1.mol
• Article Data: 21

Chemical Properties

• Melting Point: 255 °C (dec.)(lit.)
• Boiling Point: 689.3 °C at 760 mmHg
• Flash Point: 370.7 °C
• Appearance: /
• Density: 1.532
• Vapor Pressure: 5.96E-20mmHg at 25°C
• Refractive Index: 1.799
• Storage Temp.: 2-8°C(protect from light)
• Solubility: Aqueous Base, DMSO
• PKA: 4.63±0.10(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: 4-[N-(2,4-DIAMINO-6-PTERIDINYLMETHYL)-N-METHYLAMINO] BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[N-(2,4-DIAMINO-6-PTERIDINYLMETHYL)-N-METHYLAMINO] BENZOIC ACID(19741-14-1)
• EPA Substance Registry System: 4-[N-(2,4-DIAMINO-6-PTERIDINYLMETHYL)-N-METHYLAMINO] BENZOIC ACID(19741-14-1)

Safety Data

• Hazard Codes: Xi
• Statements: 43-52/53
• Safety Statements: 36/37
• WGK Germany: 3
• Hazardous Substances Data: 19741-14-1(Hazardous Substances Data)

Usage

Description

4-[N-(2,4-DIAMINO-6-PTERIDINYLMETHYL)-N-METHYLAMINO] BENZOIC ACID, also known as DAMPA, is a Methotrexate analog with a complex chemical structure. It is a brownish yellow to orange solid and has been identified as an antitumor agent.

Uses

Used in Pharmaceutical Industry:
4-[N-(2,4-DIAMINO-6-PTERIDINYLMETHYL)-N-METHYLAMINO] BENZOIC ACID is used as an antitumor agent for its potential to treat cancer. As a Methotrexate analog, it may exhibit similar properties and mechanisms of action, which could be harnessed for therapeutic purposes in oncology.

InChI:InChI=1/C15H15N7O2/c1-22(10-4-2-8(3-5-10)14(23)24)7-9-6-18-13-11(19-9)12(16)20-15(17)21-13/h2-6H,7H2,1H3,(H,23,24)(H4,16,17,18,20,21)

Upstream product

• 127-19-5 N,N-dimethyl acetamide 
• 945-24-4 2,4-diamino-6-(hydroxymethyl)pteridine 
• 150-13-0 4-amino-benzoic acid 
• 59368-16-0 6-bromomethyl-pteridine-2,4-diamine 
• 10541-83-0 N-methyl-p-aminobenzoic acid 
• 18358-63-9 methyl 4-(N-methyl)aminobenzoate 
• 73978-41-3 2,4-diamino-6-(hydroxymethyl)pteridine hydrochloride 
• 23853-09-0 4-[(2,4-diaminopteridin-6-ylmethyl)-N-methylamino]benzoic acid methyl ester 
• 52853-40-4 6-bromomethyl-2,4-diaminopteridine hydrobromide 
• 5221-17-0 2,3-dibromopropanal 
• 59-05-2 N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid 
• 7532-09-4 methotrexate sodium salt 
• 131215-19-5 γ-tert-butyl α-methyl N-(4-amino-4-deoxy-N¹⁰-methylpteroyl)-4-cyanoglutamate 
• 1004-74-6 2,4,5,6-tetraaminopyrimidine 

Downstream Products

• 1177418-19-7 C₅₈H₇₈N₁₄O₁₃ 
• 181040-33-5 N^α-[[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-(α-tert-butoxy)glutamoyl]-N-[2-[(1-oxohexadecyl)oxy]-1,1-bis[[(1-oxohexadecyl)oxy]methyl]ethyl]glycinamide 
• 181040-49-3 N^α-[[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-(α-tert-butoxy)glutamoyl]-N-[1-hydroxymethyl-2-[(1-oxohexadecyl)oxy]-1-[(1-oxohexadecyl)oxymethyl]ethyl]glycinamide 
• 511544-99-3 N^α-[[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-(α-tert-butoxy)glutamoyl]-N-[1,1-bis(hydroxymethyl)-2-[(1-oxohexadecyl)oxy]ethyl]glycinamide 
• 181040-47-1 N^α-[[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-(α-tert-butoxy)glutamoyl]-N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycinamide 
• 67022-39-3 γ-methyl N'-<4--N-methylamino>benzoyl>-L-glutamate 
• 79640-70-3 (S)-5-(tert-butoxy)-4-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)-5-oxopentanoic acid 
• 844486-60-8 2-{4-tert-butoxycarbonyl-2-[4-tert-butoxycarbonyl-2-(4-tert-butoxycarbonyl-4-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-butyrylamino)-butyrylamino]-butyrylamino}-pentanedioic acid 5-tert-butyl ester 
• 89106-05-8 2-{4-[(2,4-diamino-6-pteridinylmethyl)methylamino]benzoylamino}pentanedioic acid 1-benzyl ester 

Relevant articles and documents

Methotrexate prodrugs sensitive to reactive oxygen species for the improved treatment of rheumatoid arthritis

Methotrexate (MTX) is the standard of care in the treatment of rheumatoid arthritis (RA), a common autoimmune disease that is characterized by chronic inflammation in the synovial membrane of joints. Unfortunately, MTX suffers from high discontinuation ra

ANTIFOLATE-CARRYING NANOPARTICLES AND THEIR USE IN MEDICINE

The present invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: (i) at least one dilution ligand comprising a carbohydrate, glutathione or an ethylene glycol-containing moiety; and (ii) a ligand of the formula D-L1-Z-L2, wherein D comprises an antifolate drug or folic acid, L1 comprises a first linker portion comprising a C2-C12 glycol and/or C2-C12 alkyl chain, L2 comprises a second linker portion comprising a C2-C12 glycol and/or C2-C12 alkyl chain, wherein L1 and L2 may be the same or different, and wherein Z represents a carbonyl-containing group linking L1 and L2, and wherein L2 is coupled to said core, Also provided are pharmaceutical compositions comprising such nanoparticles, medical uses thereof and methods for producing the nanoparticles.

PROTEIN DEGRADATION INDUCING TAG AND USAGE THEREOF

Provided are: a protein degradation inducing tag which is a molecule that has affinity with proteases and does not inhibit degradation of a protein by proteases; a protein degradation inducing molecule that is a conjugate of at least one protein degradation inducing tag and at least one protein binding molecule that binds to a protein; and a usage of those.